ConductScience.org, home

Paper1640487

Multiparametric prognostic evaluation of biological factors in primary breast cancer.

Spyratos F and 9 others. J Natl Cancer Inst, 1992. Cited by 120 papers, by iCite.

Cite this record

ConductScience Library. Multiparametric prognostic evaluation of biological factors in primary breast cancer. Papers, record 1640487. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1640487

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1992
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
120
iCite
Relative citation ratio, by iCite
3.95
iCite
Revised in PubMed
2019-05-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Spyratos FF
2Martin PMP M
3Hacène KK
4Romain SS
5Andrieu CC
6Ferrero-Poüs MM
7Deytieux SS
8Le Doussal VV
9Tubiana-Hulin MM
10Brunet MM

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Cathepsin DMajor topic
DNA, NeoplasmMajor topic
Urokinase-Type Plasminogen ActivatorMajor topic
Adult
Aged
Aged, 80 and over
Cell Division
Chi-Square Distribution
Female
Flow Cytometry
Humans
Lymphatic Metastasis
Middle Aged
Multivariate Analysis
Prognosis
Retrospective Studies

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 120 citations.

PMIDTitleJournalYearIn PapersSource
30646864Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.BMC Cancer2019https://conductscience.org/library/papers/30646864PubMed
28922402New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.PLoS One2017https://conductscience.org/library/papers/28922402PubMed
25677449uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Breast Cancer Res2014https://conductscience.org/library/papers/25677449PubMed
22350496Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?Curr Treat Options Oncol2012https://conductscience.org/library/papers/22350496PubMed
10408848Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.Br J Cancer1999https://conductscience.org/library/papers/10408848PubMed
10389993
Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Br J Cancer1999https://conductscience.org/library/papers/10389993PubMed
10098758Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.Br J Cancer1999https://conductscience.org/library/papers/10098758PubMed
9836475
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Br J Cancer1998https://conductscience.org/library/papers/9836475PubMed
9662256Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.Br J Cancer1998https://conductscience.org/library/papers/9662256PubMed
9652768Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.Br J Cancer1998https://conductscience.org/library/papers/9652768PubMed
9591698Prognostic significance of cell cycle parameters in infiltrative ductal breast carcinoma.J Clin Lab Anal1998https://conductscience.org/library/papers/9591698PubMed
9528837Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.Br J Cancer1998https://conductscience.org/library/papers/9528837PubMed
9195286Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy.Invest New Drugs1997https://conductscience.org/library/papers/9195286PubMed
8944332Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.Breast Cancer Res Treat1996https://conductscience.org/library/papers/8944332PubMed
8297742Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.Br J Cancer1994https://conductscience.org/library/papers/8297742PubMed
7819033Stromal cell cathepsin D expression and long-term survival in breast cancer.Br J Cancer1995https://conductscience.org/library/papers/7819033PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CTSD1509PubTator's text mininghttps://conductscience.org/library/genes/1509NCBI Gene
PLAU5328PubTator's text mininghttps://conductscience.org/library/genes/5328NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1640487

GET https://conductscience.org/api/papers/v1/1640487/authors